AI-Powered Diagnostics for Antimicrobial Resistance (AMR)
Revolutionizing Infection Treatment with AI-Driven Insights
Antimicrobial resistance (AMR) is a growing global crisis, with over 1.27 million deaths annually linked to drug-resistant infections (The Lancet, 2022). In Pakistan alone, 70% of bacterial infections show resistance to common antibiotics, making treatment failures more frequent and dangerous (NIH Pakistan, 2023). PathoPrint is on a mission to change that.
The AMR Crisis – Why It Matters
Global Impact
- 1.27 million deaths per year due to drug-resistant infections (The Lancet, 2022).
- By 2050, AMR could cause 10 million deaths annually, surpassing cancer (WHO).
- The economic burden of AMR is projected to reach $100 trillion globally (World Bank).
Pakistan’s Growing AMR Challenge
- 70% of bacterial infections in Pakistan are resistant to commonly used antibiotics (NIH Pakistan, 2023).
- Urinary tract infections (UTIs) in Pakistan
- 60% caused by E. coli, with 50% resistance to ciprofloxacin (PMC, 2024).
- 45% of Klebsiella pneumoniae infections are resistant to carbapenems—last-resort antibiotics (WHO GLASS, 2024).
- Pakistan is among the countries significantly affected by AMR (WHO GLASS, 2024).
How PathoPrint Works
- Step 01
AI-Powered Data Collection
Integrates Culture & Sensitivity (C/S) test reports from hospitals, labs, and research institutions.
- Step 02
Resistance Pattern Analysis
Uses machine learning to detect regional & hospital-specific AMR trends.
- Step 03
Smart Antibiotic Recommendations
AI suggests optimized treatment options based on real-time bacterial resistance data.
- Step 04
Continuous Learning & Improvement
Updates its AMR prediction model as new lab data becomes available.
PathoPrint aims to assist doctors and healthcare providers in making data-driven antibiotic decisions, with the goal of reducing treatment failures and supporting AMR control efforts.
Who Can Benefit from PathoPrint?
Hospitals & Clinics
AI-powered reports for faster, more accurate treatment decisions.
Diagnostic Labs
Upgrade traditional C/S tests with AI-driven insights.
Doctors & Pharmacists
Reduce treatment failures and improve patient outcomes.
Government & Public Health Agencies
Track nationwide AMR trends for better policymaking.
Pharmaceutical Companies
Get AI-driven insights into bacterial resistance patterns for drug development.
AI-Powered Diagnostics for Antimicrobial Resistance (AMR)
- AI-Powered Precision: Real-time AMR predictions improve treatment accuracy.
- Data-Driven Insights: Provides hospital-specific resistance trends to guide antibiotic choices.
- Scalable & Impactful: Can integrate with hospitals, research labs, and national health programs.
- Fighting AMR in Pakistan & Beyond: Supports WHO’s AMR action plan and aligns with global health initiatives.
Join the Fight Against AMR
PathoPrint is currently partnering with hospitals, research institutions, and healthcare organizations to build the most advanced AI-driven AMR diagnostic tool.
- Want to collaborate?
- Contact us to explore partnerships and pilot programs.
- Interested in our research?
- Join our network of experts fighting AMR with AI-driven innovation.
